# ORIGINAL ARTICLE



# WILEY

# The impact of the muscle mass-to-fat ratio on the prognosis of patients undergoing pancreaticoduodenectomy for pancreatic cancer

Long-Jie Xu 💿 | Sheng-Qiang Zhang 💿 🕴 Chun Cao 💿

Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China

### Correspondence

Chun Cao, Department of General Surgery, Second Affiliated Hospital of Soochow University, Suzhou 215004, China. Email: caochunnj@163.com

Funding information National Natural Science Foundation of China,

Grant/Award Number: 82202369

## Abstract

To evaluate the relationship between the muscle mass-to-fat ratio (MMFR) at the third lumbar spine (L3) and overall survival (OS) as well as related complications after pancreaticoduodenectomy (PD) for pancreatic cancer. Patients who underwent PD for pancreatic cancer between March 2017 and May 2023 at the Second Affiliated Hospital of Soochow University were included. Muscle mass and fat content at the L3 were measured by computed tomography. The specific formula that was used to calculate the MMFR was total abdominal muscle area/(subcutaneous adipose tissue area + visceral adipose tissue area), and the optimal cutoff values of the MMFR based on receiver operating characteristic curves were 0.688 for males and 0.382 for females. Patient characteristics were collected, and multivariate analyses were used to evaluate the impact of the MMFR on prognosis. Kaplan-Meier survival curves and log-rank tests were used to compare OS between the high-MMFR and low-MMFR groups. On the basis of the optimal cutoff values, 191 patients were divided into two groups, with 91 patients in the low-MMFR group and 100 patients in the high-MMFR group. The incidence of POPF was significantly greater in the low-MMFR group than in the high-MMFR group. According to multivariate analysis, the MMFR was an independent factor associated with POPF and OS. Patients with low MMFRs had significantly shorter OS and a greater POPF incidence than did those with high MMFRs. The MMFR is an independent predictor of POPF and affects the OS of patients undergoing PD for pancreatic cancer.

# KEYWORDS

complications, muscle mass-to-fat ratio, overall survival, pancreatic cancer, pancreaticoduodenectomy

# 1 | INTRODUCTION

Considering its high mortality and morbidity rates and poor prognosis, pancreatic cancer is a fatal disease. Pancreatic cancer diagnoses have doubled worldwide in the past two decades.<sup>1</sup> In addition, pancreatic

cancer is the 7th leading cause of cancer-related deaths worldwide, and the 5-year survival rate is only 9%.<sup>2</sup> Currently, various treatment options for pancreatic cancer are available, including preoperative neoadjuvant chemotherapy, postoperative adjuvant chemotherapy, and targeted therapy. However, despite its high recurrence rate,

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Author(s). The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Kaohsiung Medical University.

KIMS

surgery remains the most effective treatment for pancreatic cancer.<sup>3</sup> The main surgical method for treating pancreatic cancer, especially for malignant cancer of the pancreatic head, is pancreaticoduodenectomy (PD). Although comprehensive perioperative management has improved the overall survival (OS) and recurrence-free survival of patients undergoing surgery and has made PD a safer procedure, this operation still has a high risk of morbidity and mortality.<sup>4</sup> The major postoperative complications include postoperative pancreatic fistula (POPF), gastroplegia, bile leakage, chylous fistula, and intra-abdominal abscess, and the occurrence of these complicates indicates a poor prognosis after surgery.<sup>5</sup> In particular, POPF is the most common complication, the incidence of which reaches 29%.<sup>6</sup> Patients who develop POPF are more likely to suffer from bleeding and intraabdominal infection.<sup>7</sup> Therefore, accurate indicators that can be used to precisely evaluate surgical complications and OS are needed to help clinicians tailor treatment and improve long-term survival.

Most recent studies have focused on the correlation between sarcopenia and the prognosis of malignant cancers. Sarcopenia has been reported to be associated with a poor prognosis in patients with lung cancer; these patients have a 4% increased risk of death for every unit of muscle mass lost.<sup>8</sup> In addition, sarcopenia serves as a prognostic biomarker in patients with bladder cancer and gastric cancer and can lead to prolonged hospital stays, increased postoperative complications, and reduced quality of life.9 The progression-free survival of patients with gastric cancer complicated by sarcopenia is significantly shorter than that of patients without sarcopenia.<sup>10</sup> Among patients receiving palliative and curative treatment for pancreatic cancer, those with sarcopenia have poorer OS and shorter rates of disease-free survival.<sup>11,12</sup> However, several studies suggest that fat mass is also essential for evaluating the prognosis of patients with malignant cancers. It has been reported that the visceral fat area is an independent predictor of OS in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.<sup>13</sup> A greater subcutaneous fat area is significantly associated with shorter OS in patients with gastric cancer.<sup>14</sup> Skeletal muscle fat infiltration is an exact predictor of poor survival after surgery for gallbladder cancer and is a stronger predictor of survival than the quantity of skeletal muscle.<sup>15</sup> A high ratio of the visceral fat area to the psoas muscle area is an independent prognostic factor for poor OS in patients after surgical resection of esophageal cancer.<sup>16</sup> In addition, women who have a high fat-to-muscle ratio are more likely to develop breast cancer.<sup>17</sup> Moreover, many studies have indicated that body composition plays a role in predicting the prognosis and OS of patients with pancreatic cancer. Several studies have emphasized the importance of decreasing muscle mass, which predicts poor OS after PD.<sup>3</sup> An increased visceral fat tissue volume, as measured by computed tomography (CT), is also associated with the development of POPF after PD.<sup>6</sup> The ratio of muscle to fat, as analyzed by bioelectrical impedance, is a predictor of cardiometabolic risk, such as coronary artery disease.<sup>18</sup> However, it remains unclear whether the ratio of skeletal muscle mass to total fat, as measured at the third lumbar spine (L3) by CT, is a superior predictor of postoperative complications and OS in patients after PD.

In this study, we aimed to evaluate the relationship between the muscle mass-to-fat ratio (MMFR) at the L3 level and OS as well as related complications after PD in pancreatic cancer patients.

#### MATERIALS AND METHODS 2 |

#### 2.1 Study population


A total of 200 patients who underwent PD from March 2017 to May 2023 at the Second Affiliated Hospital of Soochow University and who had a postoperative pathological diagnosis of pancreatic cancer were included in the study. Patients who did not undergo preoperative CT (9 patients) were excluded. Ultimately, a total of 191 patients were enrolled. Informed consent was obtained from all the patients. and the study was approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University (JD-HG-2023-0017).

#### 2.2 CT image acquisition and management

After locating the position of L3, cross-sectional images were collected for all patients. Each image was analyzed via SliceOmatic software 5.0 (TomoVision, USA) according to the standard Hounsfield Unit (HU) range. The subcutaneous adipose tissue (SAT) area at -190to -30 HU, the visceral adipose tissue (VAT) area at -150 to -50 HU, and the total abdominal muscle (TAMA) area at -29 to 150 HU were determined. The body composition of the participants is shown in Figure 1.

#### **Patient characteristics** 2.3

The patients' background and preoperative characteristics included sex, age, body mass index (BMI), visceral-to-subcutaneous adipose tissue area ratio (VSR), sarcopenia status, preoperative serious underlying disease, and preoperative laboratory examination (conducted 2 days before surgery). Intraoperative characteristics included operation time, amount of bleeding, main pancreatic duct (MPD) diameter, anastomosis of pancreatojejunostomy method, vascular reconstruction, pancreatic texture (defined as soft or hard according to the intraoperative judgment of the operating surgeons), blood transfusion, vascular invasion, nerve invasion, and lymphatic invasion. Postoperative characteristics included intensive care unit (ICU) admission status, hospital stay, postoperative hospital stay, hospitalization expenses, tumor-lymph node-metastasis (TNM) stage, postoperative laboratory examination on postoperative day (POD) 3, mortality, survival time, and overall complications, such as POPF, bile leakage, chylous fistula, gastrointestinalgia, sepsis, hemorrhage, organ space surgical site infection (SSI), incisional SSI, intestinal obstruction, reoperation, thrombotic events, pneumonia, cardiopulmonary events, and Clavien-Dindo classification (CDC).



**FIGURE 2** Receiver operating characteristic curve for the MMFR stratified by sex. (A) male, the area under the curve = 0.643; sensitivity = 61.0%; specificity = 64.1%. (B) female, the area under the curve = 0.636; sensitivity = 62.0%; specificity = 68.0%.

# 2.4 | Definition of body composition

The specific formula for calculating the MMFR was TAMA/(SAT + VAT), which was based on our previous study,<sup>19</sup> and the optimal cutoff values of the MMFR based on receiver operating characteristic (ROC) curves were 0.688 for males and 0.382 for females (Figure 2). Sarcopenia was defined as a skeletal muscle index (SMI) <41 cm<sup>2</sup>/m<sup>2</sup> in females and <43 cm<sup>2</sup>/m<sup>2</sup> in males with a BMI <25 kg/m<sup>2</sup> and <53 cm<sup>2</sup>/m<sup>2</sup> in males with a BMI >25 kg/m<sup>2</sup>. The VSR refers to the ratio of VAT to SAT, and the optimal cutoff value of the VSR based on the ROC curves was 0.486.

# 2.5 | Statistical analyses

Continuous variables are expressed as medians and interquartile ranges (IQRs). The Kolmogorov–Smirnov test was used to test the normality of the data. Normally distributed variables were analyzed by Student's *t* test, and nonnormally distributed variables were analyzed by the nonparametric Mann–Whitney *U* test. Categorical variables are expressed as numbers and percentages and were analyzed by the chi-square test or Fisher's exact test. The factors that were significantly different (p < 0.1) according to univariate logistic regression were included in the multivariate analysis. The Cox proportional hazards

4 of 12 WILEY Medical Sciences KIMS

model was used for survival analysis, and all factors that were significantly correlated (p < 0.1) with OS were entered into the multivariate analysis. The results are reported as the adjusted odds ratio (OR) with the corresponding 95% confidence interval (CI). Survival curves were analyzed via Kaplan-Meier curves and compared via the log-rank test. All tests were two-sided, and p < 0.05 was used as an indicator of statistical significance. All the statistical analyses were performed via SPSS software 26.0 (SPSS, Chicago, IL, USA).

#### 3 RESULTS

Among the 191 patients enrolled, 116 (60.7%) were male, the median age was 68 years (IQR: 60-73 years), and the BMI was 22.2 kg/m<sup>2</sup> (IQR: 20.3-24.5 kg/m<sup>2</sup>). Ninety-one patients met the criteria for inclusion in the low-MMFR group, and 100 patients met the criteria for inclusion in the high-MMFR group according to the optimal cutoff values stratified by sex.

#### 3.1 Baseline characteristics according to the MMFR

There were significant differences between the high-MMFR and low-MMFR groups in terms of preoperative baseline characteristics, including age (p = 0.042), BMI (p < 0.001), VSR (p < 0.001), hemoglobin (Hb) (p = 0.001), globulin (p = 0.033), and fibrinogen (p = 0.048). However, sex, sarcopenia status, preoperative serious underlying disease status, and other preoperative laboratory data were not significantly different between the two groups (Table 1).

#### 3.2 Intraoperative characteristics according to the MMFR

As shown in Table 2, the pancreatic texture significantly differed between the low-MMFR and high-MMFR groups (p = 0.004). However, other intraoperative characteristics, including the operation time, amount of bleeding, MPD diameter, anastomosis of pancreatojejunostomy method, vascular reconstruction, blood transfusion, vascular invasion, nerve invasion, and lymphatic invasion, were not different between the two groups.

#### Postoperative complications and 3.3 characteristics according to the MMFR

The overall complication rate was significantly different between the high-MMFR and low-MMFR groups (p = 0.012). In particular, the incidences of POPF, bile leakage, and organ space SSI were significantly lower in the high-MMFR group than in the low-MMFR group (p < 0.001; p = 0.043; p = 0.045, respectively). However, other complications, including chylous fistula, gastroplegia, sepsis, hemorrhage,

incisional SSI, intestinal obstruction, thrombotic events, pneumonia, and cardiopulmonary events, were not different between the two groups. In addition, there were no significant differences between the two groups in terms of reoperation, ICU admission status, hospital stay, postoperative hospital stay, hospitalization expense, or TNM stage. The levels of neutrophils, C-reactive protein (CRP), fibrinogen, and lactate dehydrogenase on POD 3 were significantly lower in the high-MMFR group than in the low-MMFR group (p = 0.030; p = 0.002; p = 0.024; p = 0.008, respectively). In addition, the levels of albumin and prealbumin were significantly greater in the high-MMFR group than in the low-MMFR group (p = 0.005; p < 0.001, respectively). The other postoperative laboratory examinations revealed no significant differences (Table 3).

#### 3.4 Univariate and multivariate logistic regression analyses of risk factors for POPF

As shown in Table 4, the VSR, MPD diameter, MMFR, pancreatic texture, lymphatic invasion, preoperative white blood cell count, CRP, albumin/globulin, alanine aminotransferase, and alkaline phosphatase concentrations were determined via univariate analysis. Multivariate logistic regression analysis confirmed that MPD diameter (OR, 10.76; 95% CI, 4.666-24.83; p = 0.001), MMFR (OR, 2.894; 95% CI, 1.214-6.899; p = 0.017), lymphatic invasion (OR, 4.590; 95% Cl, 1.599-13.17; p = 0.005), and CRP (OR, 2.943; 95% Cl, 1.061-8.158; p = 0.038) were independent predictors of POPF.

#### 3.5 OS analysis

The results of univariate and multivariate Cox regression analyses of OS among patients who underwent PD for pancreatic cancer are shown in Table 5. According to the univariate analysis, age, vascular reconstruction, sarcopenia, MMFR, ICU admission status, blood transfusion, nerve invasion, lymphatic invasion, sepsis, and cardiopulmonary events were significant predictors of OS after surgery. Multivariate analysis revealed that vascular reconstruction (HR, 4.120; 95% CI, 1.235-13.75; p = 0.021), sarcopenia (HR, 1.778; 95% CI, 1.124-2.811; p = 0.014), MMFR (HR, 1.718; 95% CI, 1.084-2.723; p = 0.021), ICU admission status (HR, 1.907; 95% CI, 1.078-3.373; p = 0.026), and nerve invasion (HR, 1.734; 95% CI, 1.101-2.730; p = 0.017) were independent predictors of OS. Moreover, the OS curves revealed that patients with low MMFRs had significantly shorter OS than did those with high MMFRs (p = 0.014) (Figure 3).

#### DISCUSSION 4

In this study, the MMFR was identified as an independent predictor of OS by both univariate and multivariate Cox regression analyses. In addition, multivariate logistic regression analysis identified the MMFR as an independent prognostic factor for POPF in patients with

XU ET AL.

**TABLE 1** Patient demographic and clinical characteristics according to the MMFR.

Variable	High MMFR ( $n = 100$ )	Low MMFR ( $n = 91$ )	p value
Sex			
Male	61 (61.0%)	55 (60.4%)	0.937
Female	39 (39.0%)	36 (39.6%)	
Age (years)	66 (57, 73)	69 (63, 74)	0.042*
BMI (kg/m <sup>2</sup> )	20.95 (19.29, 22.83)	24.00 (22.04, 25.61)	<0.001*
VSR	0.737 (0.474, 1.032)	1.121 (0.770, 1.481)	<0.001*
Sarcopenia			
Yes	52 (52.0%)	48 (52.7%)	0.918
No	48 (48.0%)	43 (47.3%)	
Preoperative serious underlying	g disease		
Yes	6 (6.0%)	2 (2.2%)	0.283
No	94 (94.0%)	89 (97.8%)	
Preoperative laboratory examin	ation		
WBC ( $\times$ 10 <sup>9</sup> /L)	5.9 (4.3, 7.6)	5.8 (4.7, 7.3)	0.701
Lymphocyte ( $ imes$ 10 <sup>9</sup> /L)	1.4 (1.0, 1.6)	1.3 (1.1, 1.7)	0.654
Neutrophil ( $\times$ 10 <sup>9</sup> /L)	3.6 (2.5, 5.1)	3.8 (2.7, 5.0)	0.478
Platelet ( $\times$ 10 <sup>9</sup> /L)	240 (171, 284)	236 (198, 295)	0.517
Hb (g/L)	117 (107, 129)	126 (113, 138)	0.001*
CRP (mg/L)	5.5 (5.1, 7.2)	5.5 (4.8, 6.4)	0.624
Albumin (g/L)	39.0 (36.4, 43.0)	40.4 (37.4, 44.7)	0.050
Globulin (g/L)	27.0 (24.1, 29.6)	27.9 (26.2, 31.4)	0.033*
Albumin/Globulin	1.43 (1.25, 1.67)	1.43 (1.26, 1.60)	0.527
Prealbumin (g/L)	0.21 (0.15, 0.25)	0.18 (0.13, 0.24)	0.208
INR	1.00 (0.95, 1.06)	1.00 (0.95, 1.05)	0.755
APTT (s)	36.3 (33.1, 39.6)	35.0 (32.8, 38.8)	0.268
PT (s)	13.0 (12.6, 13.7)	13.1 (12.6, 13.6)	0.913
Fibrinogen (mg/dL)	3.62 (2.89, 4.55)	3.92 (3.19, 4.81)	0.048*
TBil (μmol/L)	28.9 (10.0, 103.2)	17.7 (10.8, 72.5)	0.495
ALT (U/L)	52 (17, 88)	40 (16, 109)	0.855
AST (U/L)	37 (20, 63)	29 (17, 78)	0.642
ALP (U/L)	201 (85, 437)	123 (82, 336)	0.158
LDH (U/L)	172 (148, 195)	174 (156, 206)	0.267
GGT (U/L)	198 (33, 533)	142 (29, 479)	0.653

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; GGT, gamma glutamyl transferase; Hb, hemoglobin; INR, international normalized ratio; LDH, lactate dehydrogenase; MMFR, muscle mass-to-fat ratio; PT, prothrombin time; TBil, total bilirubin; VSR, visceral-to-subcutaneous adipose tissue area ratio; WBC, white blood cell. \*p < 0.05.

pancreatic cancer. These results indicated a strong correlation between the preoperative MMFR and the prognosis of patients after PD, suggesting that adding the MMFR could aid in the critical optimization of prognostic prediction models for pancreatic cancer.

Pancreatic cancer, characterized by inapparent early symptoms and difficult diagnosis, is a malignant cancer with a high mortality rate and poor prognosis. Surgical treatment has been the only radical treatment for pancreatic cancer, but its poor prognosis has been a major problem. Recently, many studies have explored the relationship between body composition and postoperative prognosis in PD patients, and they have shown that muscle mass and fat components are associated with the prognosis of PD.<sup>20–22</sup> According to our study, the level of postoperative albumin was significantly lower in patients with low MMFRs than in patients with high MMFRs; low postoperative albumin levels predict susceptibility to malnutrition and increase the risk of delayed anastomotic and incisional healing and abdominal infection in patients with low MMFRs. Recent studies have shown that nutritional support can regulate innate immunity and

Operation time (min) $320 (300, 360)$ $345 (300, 395)$ $0.104$ Amount of bleeding (mL) $300 (163, 400)$ $300 (200, 500)$ $0.213$ MPD diameter (mm) $42 (46.2\%)$ $0.154$ $< 3 mm$ $64 (64.0\%)$ $42 (46.2\%)$ $0.154$ $\geq 3 mm64 (64.0\%)49 (53.8\%)0.643Methods of anastomosisTTTContinuous suture55 (55.0\%)47 (51.6\%)0.643"8-character" suture45 (45.0\%)44 (48.4\%)0.643Vascular reconstructionTTTYes1 (1.0\%)3 (3.3\%)0.548No99 (90\%)88 (96.7\%)0.004^*Pancreatic textureTTTSoft26 (26.0\%)42 (46.2\%)0.004^*Hard74 (74.0\%)49 (53.8\%)TBlood transfusionTTTYes25 (25.0\%)22 (24.2\%)0.695No75 (75.0\%)69 (75.8\%)TNo75 (75.0\%)69 (75.8\%)TNo58 (58.0\%)55 (60.4\%)TNo58 (58.0\%)55 (60.4\%)TLymphatic invasionTTTYes29 (29.0\%)24 (26.4\%)0.686No71 (71.0\%)67 (73.6\%)T$	Variable	High MMFR ( $n = 100$ )	Low MMFR (n = 91)	p value
MPD diameter (mm)36 (36.0%)42 (46.2%)0.154 $\leq$ 3 mm64 (64.0%)49 (53.8%)0Methods of anastomosis $\qquad$ $\qquad$ Continuous suture55 (55.0%)47 (51.6%)0.643"8-character" suture45 (45.0%)44 (48.4%)0Vascular reconstruction $\qquad$ $\qquad$ $\qquad$ Yes1 (1.0%)3 (3.3%)0.548No99 (99.0%)88 (96.7%)0Pancreatic texture $\qquad$ $\qquad$ Soft26 (26.0%)42 (46.2%)0.004*Hard74 (74.0%)49 (53.8%)0Blood transfusion $\qquad$ $\qquad$ $\qquad$ Yes26 (26.0%)32 (35.2%)0.169No74 (74.0%)59 (64.8%)0Vascular invasion $\qquad$ $\qquad$ Yes25 (25.0%)22 (24.2%)0.895No75 (75.0%)69 (75.8%)0No58 (58.0%)55 (60.4%)0.732No58 (58.0%)55 (60.4%)0.732Yes42 (42.0%)36 (39.6%)0.732No58 (58.0%)55 (60.4%)0.732Yes29 (29.0%)24 (26.4%)0.686	Operation time (min)	320 (300, 360)	345 (300, 395)	0.104
$<3 \text{ nm}$ $36 (36.0\%)$ $42 (46.2\%)$ $0.154$ $\geq 3 \text{ nm}$ $64 (64.0\%)$ $49 (53.8\%)$ $M$ Methods of anastomosis $X$ $X$ Continuous suture $55 (55.0\%)$ $47 (51.6\%)$ $0.643$ "8-character" suture $45 (45.0\%)$ $44 (48.4\%)$ $0.643$ Vascular reconstruction $X$ $X$ $X$ Yes $1 (1.0\%)$ $3 (3.3\%)$ $0.548$ No $99 (99.0\%)$ $88 (96.7\%)$ $0.004^*$ Pancreatic texture $X$ $X$ $X$ Soft $26 (26.0\%)$ $42 (46.2\%)$ $0.004^*$ Hard $74 (74.0\%)$ $49 (53.8\%)$ $0.004^*$ Blood transfusion $X$ $X$ $X$ Yes $26 (26.0\%)$ $32 (35.2\%)$ $0.004^*$ No $74 (74.0\%)$ $59 (64.8\%)$ $0.004^*$ No $75 (75.0\%)$ $69 (75.8\%)$ $0.732$ No $75 (75.0\%)$ $69 (75.8\%)$ $0.732$ No $75 (75.0\%)$ $56 (60.4\%)$ $0.732$ No <td< td=""><td>Amount of bleeding (mL)</td><td>300 (163, 400)</td><td>300 (200, 500)</td><td>0.213</td></td<>	Amount of bleeding (mL)	300 (163, 400)	300 (200, 500)	0.213
≥3 mm64 (64.0%)49 (53.8%)Methods of anastomosis $($ Continuous suture55 (55.0%)47 (51.6%)0.643"8-character" suture45 (45.0%)44 (48.4%) $($ Continuous suture $($ Soft26 (26.0%)3 (3.3%)0.548No99 (99.0%)88 (96.7%) $($ Soft26 (26.0%)42 (46.2%)0.004*Pancreatic texture $($ Soft26 (26.0%)42 (46.2%)0.004*Hard74 (74.0%)49 (53.8%) $($ Soft0.169Blood transfusion $($ Yes26 (26.0%)32 (35.2%)0.169Vascular invasion $($ Yes25 (25.0%)22 (24.2%)0.895No75 (75.0%)69 (75.8%) $($ Soft $($ Soft (39.6%) $($ Soft)Nerve invasion $($ Yes42 (42.0%)36 (39.6%) $($ Soft) $($ Soft (39.6%) $($ Soft)Verve invasion $($ Yes42 (42.0%)36 (39.6%) $($ Soft) <th< td=""><td>MPD diameter (mm)</td><td></td><td></td><td></td></th<>	MPD diameter (mm)			
Methods of anastomosis         Value         55 (55.0%)         47 (51.6%)         0.643           "8-character" suture         45 (45.0%)         44 (48.4%)         0           Vascular reconstruction         45 (45.0%)         44 (48.4%)         0           Yes         1 (1.0%)         3 (3.3%)         0.548           No         99 (99.0%)         88 (96.7%)         0           Pancreatic texture         5         5         0.004*           Soft         26 (26.0%)         42 (46.2%)         0.004*           Hard         74 (74.0%)         49 (53.8%)         0           Blood transfusion         74 (74.0%)         59 (64.8%)         0.069           Vascular invasion         75 (75.0%)         69 (75.8%)         0.6895           No         75 (75.0%)         69 (75.8%)         0.732           No         58 (58.0%)         55 (60.4%)         0.732           No         58 (58.0%)         55 (60.4%)         0.732           No         58 (58.0%)         55 (60.4%)         0.6866	<3 mm	36 (36.0%)	42 (46.2%)	0.154
Continuous suture         55 (55.0%)         47 (51.6%)         0.643           "8-character" suture         45 (45.0%)         44 (48.4%)         0           Vascular reconstruction         3 (3.3%)         0.548           No         99 (99.0%)         88 (96.7%)         0           Pancreatic texture         5         5         0         0.004*           Soft         26 (26.0%)         42 (46.2%)         0.004*           Hard         74 (74.0%)         49 (53.8%)         0           Blood transfusion         4         48.4%)         0           Yes         26 (26.0%)         32 (35.2%)         0.169           No         74 (74.0%)         59 (64.8%)         0.169           No         74 (74.0%)         59 (64.8%)         0.169           No         74 (75.0%)         69 (75.8%)         0.895           No         75 (75.0%)         69 (75.8%)         0.895           No         58 (58.0%)         55 (60.4%)         0.732           No         58 (58.0%)         55 (60.4%)         0.732           No         58 (58.0%)         55 (60.4%)         0.732           No         58 (58.0%)         55 (60.4%)         0.6866 <td>≥3 mm</td> <td>64 (64.0%)</td> <td>49 (53.8%)</td> <td></td>	≥3 mm	64 (64.0%)	49 (53.8%)	
"8-character" suture         45 (45.0%)         44 (48.4%)           Vascular reconstruction	Methods of anastomosis			
Vascular reconstruction         Yes       1 (1.0%)       3 (3.3%)       0.548         No       99 (99.0%)       88 (96.7%) $(1.00)$ Pancreatic texture         Soft       26 (26.0%)       42 (46.2%)       0.004*         Hard       74 (74.0%)       49 (53.8%) $(1.00)$ Blood transfusion $(1.00)$ 32 (35.2%)       0.169         Yes       26 (26.0%)       32 (35.2%)       0.169         No       74 (74.0%)       59 (64.8%) $(1.00)$ Vascular invasion $(1.00)$ $(2.00)$ $(2.02)$ $(2.02)$ No       75 (75.0%)       22 (24.2%) $(0.895)$ No       75 (75.0%)       69 (75.8%) $(7.32)$ Nerve invasion $(2.02)$ $(3.639.6\%)$ $(3.639.6\%)$ $(3.732)$ Yes       42 (42.0%)       36 (39.6%) $(5.732)$ $(7.32)$ No       58 (58.0%)       55 (60.4%) $(7.32)$ No       58 (58.0%)       55 (60.4%) $(6.86)$ Lymphatic invasion $(2.9)$ $(2.9)$ $(2.9)$ $(2.64\%)$ $(2.64\%)$ $(2.64\%)$ <	Continuous suture	55 (55.0%)	47 (51.6%)	0.643
Yes         1 (1.0%)         3 (3.3%)         0.548           No         99 (99.0%)         88 (96.7%)	"8-character" suture	45 (45.0%)	44 (48.4%)	
No         99 (99.0%)         88 (96.7%)           Pancreatic texture	Vascular reconstruction			
Pancreatic texture         Soft         26 (26.0%)         42 (46.2%)         0.004*           Hard         74 (74.0%)         49 (53.8%)         0           Blood transfusion	Yes	1 (1.0%)	3 (3.3%)	0.548
Soft         26 (26.0%)         42 (46.2%)         0.004*           Hard         74 (74.0%)         49 (53.8%)         0.004*           Blood transfusion         49 (53.8%)         0.004*           Yes         26 (26.0%)         32 (35.2%)         0.169           No         74 (74.0%)         59 (64.8%)         0.004*           Vascular invasion         74 (74.0%)         59 (64.8%)         0.895           No         75 (75.0%)         22 (24.2%)         0.895           No         75 (75.0%)         69 (75.8%)         0.732           Nerve invasion         742 (42.0%)         36 (39.6%)         0.732           No         58 (58.0%)         55 (60.4%)         0.686           Lymphatic invasion         742 (42.0%)         36 (39.6%)         0.686	No	99 (99.0%)	88 (96.7%)	
Hard74 (74.0%)49 (53.8%)Blood transfusionYes26 (26.0%)32 (35.2%)0.169No74 (74.0%)59 (64.8%)Vascular invasionYes25 (25.0%)22 (24.2%)0.895No75 (75.0%)69 (75.8%)Nerve invasionYes42 (42.0%)36 (39.6%)0.732No58 (58.0%)55 (60.4%)0.732Lymphatic invasionYes29 (29.0%)24 (26.4%)0.686	Pancreatic texture			
Blood transfusion           Yes         26 (26.0%)         32 (35.2%)         0.169           No         74 (74.0%)         59 (64.8%)         0           Vascular invasion         Yes         25 (25.0%)         22 (24.2%)         0.895           No         75 (75.0%)         69 (75.8%)         0         0           Nerve invasion         Yes         42 (42.0%)         36 (39.6%)         0.732           No         58 (58.0%)         55 (60.4%)         0.732           Lymphatic invasion         Yes         29 (29.0%)         24 (26.4%)         0.686	Soft	26 (26.0%)	42 (46.2%)	0.004*
Yes26 (26.0%)32 (35.2%)0.169No74 (74.0%)59 (64.8%)0Vascular invasion22 (24.2%)0.895Yes25 (25.0%)22 (24.2%)0.895No75 (75.0%)69 (75.8%)0Nerve invasion75 (75.0%)69 (75.8%)0.732Yes42 (42.0%)36 (39.6%)0.732No58 (58.0%)55 (60.4%)0Lymphatic invasion29 (29.0%)24 (26.4%)0.686	Hard	74 (74.0%)	49 (53.8%)	
No         74 (74.0%)         59 (64.8%)           Vascular invasion	Blood transfusion			
Vascular invasion         25 (25.0%)         22 (24.2%)         0.895           No         75 (75.0%)         69 (75.8%)         0           Nerve invasion         42 (42.0%)         36 (39.6%)         0.732           No         58 (58.0%)         55 (60.4%)         0.686           Lymphatic invasion         29 (29.0%)         24 (26.4%)         0.686	Yes	26 (26.0%)	32 (35.2%)	0.169
Yes     25 (25.0%)     22 (24.2%)     0.895       No     75 (75.0%)     69 (75.8%)     0       Nerve invasion	No	74 (74.0%)	59 (64.8%)	
No         75 (75.0%)         69 (75.8%)           Nerve invasion         Yes         42 (42.0%)         36 (39.6%)         0.732           No         58 (58.0%)         55 (60.4%)         0.732           Lymphatic invasion         Yes         29 (29.0%)         24 (26.4%)         0.686	Vascular invasion			
Nerve invasion         36 (39.6%)         0.732           Yes         42 (42.0%)         36 (39.6%)         0.732           No         58 (58.0%)         55 (60.4%)         0.686           Lymphatic invasion         29 (29.0%)         24 (26.4%)         0.686	Yes	25 (25.0%)	22 (24.2%)	0.895
Yes         42 (42.0%)         36 (39.6%)         0.732           No         58 (58.0%)         55 (60.4%)         0           Lymphatic invasion         Yes         29 (29.0%)         24 (26.4%)         0.686	No	75 (75.0%)	69 (75.8%)	
No         58 (58.0%)         55 (60.4%)           Lymphatic invasion         29 (29.0%)         24 (26.4%)         0.686	Nerve invasion			
Lymphatic invasion         29 (29.0%)         24 (26.4%)         0.686	Yes	42 (42.0%)	36 (39.6%)	0.732
Yes 29 (29.0%) 24 (26.4%) 0.686	No	58 (58.0%)	55 (60.4%)	
	Lymphatic invasion			
No 71 (71.0%) 67 (73.6%)	Yes	29 (29.0%)	24 (26.4%)	0.686
	No	71 (71.0%)	67 (73.6%)	

# **TABLE 2** Intraoperative characteristics according to the MMFR.

Abbreviations: MMFR, muscle mass-to-fat ratio; MPD, main pancreatic duct. \*p < 0.05.

inflammation, in turn promoting anastomotic healing and reducing the incidence of postoperative complications.<sup>23</sup> In contrast, malnutrition can reduce collagen synthesis and granuloma formation, which leads to delayed anastomotic healing and creates a favorable environment for bacterial growth, thus increasing the risk of infection. In addition, low serum albumin can lead to tissue edema by reducing the osmotic pressure of plasma colloids and promoting the leakage of tissue interstitial fluid into the wound, providing a medium for bacterial growth and further increasing the risk of infectious complications.<sup>24</sup> Patients in the low-MMFR group had significantly more neutrophils and CRP after PD, suggesting that patients with a low MMFR have severe postoperative inflammation. Recent studies have shown that visceral fat can produce adipokines, such as leptin, resistin, and adiponectin, which regulate inflammation and metabolism. Imbalances in these adipokines, particularly elevated levels of leptin, can contribute to inflammation.<sup>25</sup> In addition, visceral fat promotes the accumulation of macrophages in fat tissue by increasing local extracellular lipid concentrations, and macrophages release proinflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6,<sup>25</sup> which further exacerbates the inflammatory response. Moreover, excessive visceral

fat and less abdominal muscle could cause immune response dysregulation,<sup>26</sup> which could also contribute to severe inflammation. And we found that the VSR is greater in patients with a low MMFR. These studies may explain why patients with low MMFRs have a greater incidence of organ space SSI.

Patients in the high-MMFR group were less likely to experience overall complications than those in the low-MMFR group. POPF is the most common complication after PD, and the incidence was 33.5% in this study, which is similar to the incidence reported in a recent study.<sup>27</sup> Sarcopenia has been reported to be an independent risk factor for POPF,<sup>21</sup> and visceral fat can also independently predict POPF.<sup>28</sup> Furthermore, the ratio of visceral fat to skeletal muscle has been shown to independently predict POPF.<sup>29</sup> Our study revealed that the MMFR is a significant predictor of POPF rather than sarcopenia, and patients with a low MMFR are more likely to experience POPF. Several mechanisms may explain why patients with low MMFRs are more likely to develop POPF after PD. First, excessive abdominal fat can increase the difficulty of accessing the pancreast during surgery, possibly leading to inadvertent injury to the pancreatic duct or incomplete closure of the pancreatic stump, thereby

# **TABLE 3** Postoperative complications and characteristics according to the MMFR.

Variable	High MMFR ( $n = 100$ )	Low MMFR (n = 91)	p Value
Overall complica	itions		
Yes	60 (60.0%)	70 (76.9%)	0.012*
No	40 (40.0%)	21 (23.1%)	
POPF			
Yes	22 (22.0%)	42 (46.2%)	<0.001*
No	78 (78.0%)	49 (53.8%)	
Bile leakage	, 0 (, 0.0,0)	17 (55.570)	
Yes	12 (12.0%)	21 (23.1%)	0.043*
No	88 (88.0%)	70 (76.9%)	0.040
	00 (00.076)	70 (70.7%)	
Chylous fistula	4 (4 00/)		0.074
Yes	4 (4.0%)	7 (7.7%)	0.274
No	96 (96.0%)	84 (92.3%)	
Gastrointestinal			
Yes	30 (30.0%)	35 (38.5%)	0.218
No	70 (70.0%)	56 (61.5%)	
Sepsis			
Yes	7 (7.0%)	5 (5.5%)	0.668
No	93 (93.0%)	86 (94.5%)	
Hemorrhage			
Yes	9 (9.0%)	12 (13.2%)	0.356
No	91 (91.0%)	79 (86.8%)	
Organ space SSI			
Yes	24 (24.0%)	34 (37.4%)	0.045*
No	76 (76.0%)	57 (62.6%)	
Incisional SSI			
Yes	4 (4.0%)	5 (5.5%)	0.626
No	96 (96.0%)	86 (94.5%)	
Intestinal obstru	ction		
Yes	4 (4.0%)	7 (7.7%)	0.274
No	96 (96.0%)	84 (92.3%)	
Thrombotic ever		01()210)0)	
Yes	3 (3.0%)	4 (4.4%)	0.711
No	97 (97.0%)	87 (95.6%)	0.711
Pneumonia	77 (77.076)	07 (75.0%)	
	12 (12 0%)	17 (10 70/)	0.201
Yes	13 (13.0%)	17 (18.7%)	0.281
No	87 (87.0%)	74 (81.3%)	
Cardiopulmonar		7 /7 70/2	0.055
Yes	7 (7.0%)	7 (7.7%)	0.855
No	93 (93.0%)	84 (92.3%)	
CDC ≥ III			
Yes	37 (37.0%)	46 (50.5%)	0.059
No	63 (63.0%)	45 (49.5%)	
Reoperation			
Yes	7 (7.0%)	10 (11.0%)	0.344
No	93 (93.0%)	81 (89.0%)	

# Medical Sciences (KJMS) \_WILEY 7 of 12

# TABLE 3 (Continued)

Initial         (II = 10)         (II = 11)         (II = 11)         (II = 11)           ICU admission stature         71 (71.0%)         64 (70.3%)         0.919           No         29 (29.0%)         27 (29.7%)         1           Hospital stays         32 (26, 39)         32 (26, 43)         0.133           hospital stays         23 (18, 26)         23 (20, 33)         0.133           hospital stays         1.4.0 (8.95, 13.67)         10.88 (9.52, 14.86)         0.363           expenses (x10 <sup>4</sup> )         11.40 (8.95, 13.67)         10.88 (9.52, 14.86)         0.363           rMm stage         III         95 (95.0%)         6 (6.6%)         0.637           INM stage         III         95 (95.0%)         85 (93.4%)         0.071           Postoperative laboratory examination         WBC (x 10 <sup>9</sup> )         10.6 (7.9, 14.0)         11.8 (8.8, 16.1)         0.030*           (x 10 <sup>9</sup> /L)         0.8 (0.7, 1.0)         0.8 (0.6, 1.0)         0.326           Neutrophil         8.9 (6.5, 11.7)         10.2 (7.3, 14.0)         0.30*           (x 10 <sup>9</sup> /L)         98 (90, 108)         99 (87, 1081         0.000*           (Albumin (g/L)         95.4 (56.0, 145.8)         124.9 (77.0, 181.1)         0.002*           (Abumin (g/L)	Variable	High MMFR $(n = 100)$	Low MMFR (n = 91)	p Value
Yes71 (71.0%)64 (70.3%)0.9191No29 (29.0%)27 (29.7%)Hospital stava32 (26.39)32 (26.43)0.511Postoperative23 (18.26)23 (20.33)0.133hospital stavas23 (18.26)23 (20.33)0.133hospital stavas23 (18.26)23 (20.33)0.133hospital stavas23 (18.26)23 (20.33)0.363hospital stavas14.0 (8.95, 13.67)0.88 (9.52, 14.86)0.363hospital stavas55 (5.0%)6 (6.6%)0.637hospital stavas55 (5.0%)6 (6.6%)0.637hospital stavas0.51 (5.0%)6 (6.6%)0.637hospital stavas0.51 (5.0%)6 (6.6%)0.637hospital stavas0.51 (5.0%)6 (6.6%)0.637hospital stavas0.63 (7.10)0.8 (0.6, 1.0)0.326hospital stavas0.8 (0.7, 1.0)0.8 (0.7, 1.0)0.1027hospital stavas0.8 (0.7, 1.0)0.12 (0.7, 1.10)0.026hospital stavas0.8 (0.7, 1.0)0.12 (0.7, 1.10)0.026hospital stavas0.8 (0.7, 1.0)0.12 (0.7, 0.12)0.612hospital stavas0.12 (0.7, 1.10)0.12 (0.7, 1.10)0.612hospital stavas<				praiae
No29 (29.0%)27 (29.7%)Hospital stays (days)32 (26, 39)32 (26, 43)0.511Postoperative hospital stays (days)23 (18, 26)23 (20, 33)0.133Postoperative 			64 (70 3%)	0.919
Hospital stays (days) $32 (26, 39)$ $32 (26, 43)$ $0.511$ Postoperative hospital stays (days) $23 (18, 26)$ $23 (20, 33)$ $0.133$ Postoperative hospital stays (days) $14.0 (8.95, 13.67)$ $0.88 (9.52, 14.86)$ $0.363$ Hospitalization expenses (x104 $14.0 (8.95, 13.67)$ $0.88 (9.52, 14.86)$ $0.363$ TNM stage $11.0 (9.50.96)$ $6 (6.6%)$ $0.637$ III $5 (50.96)$ $6 (6.6%)$ $0.637$ Postoperative labor $85 (93.4%)$ $0.071$ Postoperative labor $10.6 (7.9, 14.0)$ $11.8 (8.8, 16.1)$ $0.071$ $VBC (x 10^9/)$ $0.6 (5.11.7)$ $0.8 (0.6, 1.0)$ $0.326$ $Patelet (x 10^9/L)$ $8.9 (6.5, 11.7)$ $0.2 (7.3, 14.0)$ $0.302$ Platelet $193 (144, 240)$ $182 (140, 229)$ $0.516$ $(x 10^9/L)$ $95.4 (56.0, 145.8)$ $124.9 (77.0, 181.1)$ $0.002^2$ Platelet $95.4 (56.0, 145.8)$ $124.9 (77.0, 181.1)$ $0.002^2$ Albumin (g/L) $35.1 (31.8, 37.7)$ $32.9 (30.8, 35.8)$ $0.005^2$ Globulin (g/L) $21.7 (18.7, 24.4)$ $21.1 (18.6, 23.6)$ $0.621$ Prealbumin $0.11 (0.09, 0.15)$ $0.1 (0.07, 0.12)$ $0.004^2$ INR $1.123 (1.06, 1.21)$ $1.13 (1.04, 1.23)$ $0.875$ $PT (s)$ $14.2 (13.1, 14.9)$ $14.1 (13.1, 15.2)$ $0.880$ PT (s) $14.2 (33.5.5)$ $5.1 (3.7, 5.9)$ $0.024^2$ PT (s) $14.2 (3.3, 5.5)$ $5.1 (3.7, 5.9)$ $0.024^2$ PT (brino				0.717
hospital stays expenses (×10 <sup>4</sup> )         1.4.0 (8.95, 13.67)         1.0.88 (9.52, 14.86)         0.363           TNM stage	Hospital stays			0.511
expenses (× 104 RMB)TNM stageII5 (5.0%)6 (6.6%)0.637I-II95 (95.0%)85 (93.4%)Postoperative laboratory examinationWBC (× 10 <sup>9</sup> /10.6 (7.9, 14.0)11.8 (8.8, 16.1)0.071Lymphocyte (× 10 <sup>9</sup> /L)0.8 (0.7, 1.0)0.8 (0.6, 1.0)0.326Neutrophil (× 10 <sup>9</sup> /L)8.9 (6.5, 11.7)10.2 (7.3, 14.0)0.030°Platelet 	hospital stays	23 (18, 26)	23 (20, 33)	0.133
III $5 (5.0\%)$ $6 (6.6\%)$ $0.637$ III $95 (95.0\%)$ $85 (93.4\%)$ Postoperative laboratory examinationWBC ( $\times 10^9$ / $10.6 (7.9, 14.0)$ $11.8 (8.8, 16.1)$ $0.071$ Lymphocyte ( $\times 10^9/L$ ) $0.8 (0.7, 1.0)$ $0.8 (0.6, 1.0)$ $0.326$ Neutrophil ( $\times 10^9/L$ ) $8.9 (6.5, 11.7)$ $10.2 (7.3, 14.0)$ $0.030^\circ$ Platelet ( $\times 10^9/L$ ) $193 (144, 240)$ $182 (140, 229)$ $0.516$ Hb (g/L) $98 (90, 108)$ $99 (87, 108)$ $0.774$ Albumin (g/L) $35.1 (31.8, 37.7)$ $32.9 (30.8, 35.8)$ $0.005^\circ$ Globulin (g/L) $21.7 (18.7, 24.4)$ $21.1 (18.6, 23.6)$ $0.621$ Albumin/ (g/L) $1.64 (1.43, 1.96)$ $1.59 (1.36, 1.78)$ $0.601^\circ$ Prealbumin (g/L) $0.11 (0.09, 0.15)$ $0.1 (0.07, 0.12)$ $0.001^\circ$ Prishumin/ $1.42 (13.1, 14.9)$ $1.41 (13.1, 15.2)$ $0.875$ APTT (s) $37.1 (31.2, 43.2)$ $38.9 (32.5, 43.8)$ $0.442$ PT (s) $14.2 (13.1, 14.9)$ $14.1 (13.1, 15.2)$ $0.680$ Fibrinogen (mg/dL) $26.6 (11.7, 63.5)$ $2.3 (11.9, 42.9)$ $0.837$ ALT (U/L) $31 (20.47)$ $30 (17, 48)$ $0.791$ ALT (U/L) $31 (20.47)$ $30 (15.513)$ $0.110$ Ho (U/L) $106 (73, 197)$ $100 (58, 153)$ $0.110$	expenses (×10 <sup>4</sup>	11.40 (8.95, 13.67)	10.88 (9.52, 14.86)	0.363
I-II95 (95.0%)85 (93.4%)Postoperative laboratory examinationWBC ( $\times$ 10 <sup>9</sup> /10.6 (7.9, 14.0)11.8 (8.8, 16.1)0.071Lymphocyte ( $\times$ 10 <sup>9</sup> /L)0.8 (0.7, 1.0)0.8 (0.6, 1.0)0.326Neutrophil ( $\times$ 10 <sup>9</sup> /L)8.9 (6.5, 11.7)10.2 (7.3, 14.0)0.030°Platelet ( $\times$ 10 <sup>9</sup> /L)193 (144, 240)182 (140, 229)0.516Platelet ( $\times$ 10 <sup>9</sup> /L)98 (90, 108)99 (87, 108)0.774Albumin (g/L)95.4 (56.0, 145.8)124.9 (77.0, 181.1)0.002°Albumin (g/L)35.1 (31.8, 37.7)32.9 (30.8, 35.8)0.005°Globulin (g/L)21.7 (18.7, 24.4)21.1 (18.6, 23.6)0.621Albumin/ (g/L)1.64 (1.43, 1.96)1.59 (1.36, 1.78)0.162Prealbumin (g/L)0.11 (0.09, 0.15)0.1 (0.07, 0.12)<0.001°	TNM stage			
Postoperative laboratory examinationWBC ( $\times 10^{9/}$ 10.6 (7.9, 14.0)11.8 (8.8, 16.1)0.071Lymphocyte0.8 (0.7, 1.0)0.8 (0.6, 1.0)0.326( $\times 10^{9/L}$ )8.9 (6.5, 11.7)10.2 (7.3, 14.0)0.030°Neutrophil8.9 (6.5, 11.7)10.2 (7.3, 14.0)0.030°( $\times 10^{9/L}$ )93 (144, 240)182 (140, 229)0.516Platelet193 (144, 240)182 (140, 229)0.516( $\times 10^{9/L}$ )98 (90, 108)99 (87, 108)0.774CRP (mg/L)95.4 (56.0, 145.8)124.9 (77.0, 181.1)0.002°Albumin (g/L)35.1 (31.8, 37.7)32.9 (30.8, 35.8)0.005°Globulin (g/L)21.7 (18.7, 24.4)21.1 (18.6, 23.6)0.621Albumin/1.64 (1.43, 1.96)1.59 (1.36, 1.78)0.162Globulin0.11 (0.09, 0.15)0.1 (0.07, 0.12)<0.001°	Ш	5 (5.0%)	6 (6.6%)	0.637
$\begin{array}{llllllllllllllllllllllllllllllllllll$	1–11	95 (95.0%)	85 (93.4%)	
L) Lymphocyte $0.8 (0.7, 1.0)$ $0.8 (0.6, 1.0)$ $0.326$ (× 10 <sup>9</sup> /L) Neutrophil $8.9 (6.5, 11.7)$ $10.2 (7.3, 14.0)$ $0.030^{*}$ (× 10 <sup>9</sup> /L) Platelet 193 (144, 240) $182 (140, 229)$ $0.516$ (× 10 <sup>9</sup> /L) Hb (g/L) 98 (90, 108) 99 (87, 108) $0.774$ CRP (mg/L) 95.4 (56.0, 145.8) $124.9 (77.0, 181.1)$ $0.002^{*}$ Albumin (g/L) $35.1 (31.8, 37.7)$ $32.9 (30.8, 35.8)$ $0.005^{*}$ Globulin (g/L) $21.7 (18.7, 24.4)$ $21.1 (18.6, 23.6)$ $0.621$ Albumin/ $1.64 (1.43, 1.96)$ $1.59 (1.36, 1.78)$ $0.162$ Globulin Prealbumin $0.11 (0.09, 0.15)$ $0.1 (0.07, 0.12)$ $< 0.001^{*}$ (g/L) INR $1.123 (1.06, 1.21)$ $1.13 (1.04, 1.23)$ $0.875$ APTT (s) $37.1 (31.2, 43.2)$ $38.9 (32.5, 43.8)$ $0.442$ PT (s) $14.2 (13.1, 14.9)$ $14.1 (13.1, 15.2)$ $0.680$ Fibrinogen $4.5 (3.3, 5.5)$ $5.1 (3.7, 5.9)$ $0.024^{*}$ (mg/dL) TBil (µmol/L) $26.6 (11.7, 63.5)$ $22.3 (11.9, 42.9)$ $0.839$ ALT (U/L) $31 (20, 47)$ $30 (17, 48)$ $0.792$ AST (U/L) $23 (16, 33)$ $23 (16, 30)$ $0.731$ ALP (U/L) $106 (73, 197)$ $100 (58, 153)$ $0.110$ LDH (U/L) $183 (156, 211)$ $200 (169, 241)$ $0.008^{*}$	Postoperative labo	oratory examination		
$(\times 10^{\circ}/L)$ Neutrophil ( $\times 10^{\circ}/L)$ 8.9 (6.5, 11.7)10.2 (7.3, 14.0)0.030°Platelet ( $\times 10^{\circ}/L)$ 193 (144, 240)182 (140, 229)0.516Platelet ( $\times 10^{\circ}/L)$ 193 (144, 240)182 (140, 229)0.516Hb (g/L)98 (90, 108)99 (87, 108)0.774CRP (mg/L)95.4 (56.0, 145.8)124.9 (77.0, 181.1)0.002°Albumin (g/L)35.1 (31.8, 37.7)32.9 (30.8, 35.8)0.005°Globulin (g/L)21.7 (18.7, 24.4)21.1 (18.6, 23.6)0.621Albumin/ Globulin1.64 (1.43, 1.96)1.59 (1.36, 1.78)0.162Globulin0.11 (0.09, 0.15)0.1 (0.07, 0.12)<0.001*	•	10.6 (7.9, 14.0)	11.8 (8.8, 16.1)	0.071
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	, , ,	0.8 (0.7, 1.0)	0.8 (0.6, 1.0)	0.326
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	•	8.9 (6.5, 11.7)	10.2 (7.3, 14.0)	0.030*
$\begin{array}{llllllllllllllllllllllllllllllllllll$		193 (144, 240)	182 (140, 229)	0.516
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Hb (g/L)	98 (90, 108)	99 (87, 108)	0.774
Globulin (g/L)21.7 (18.7, 24.4)21.1 (18.6, 23.6)0.621Albumin/ Globulin1.64 (1.43, 1.96)1.59 (1.36, 1.78)0.162Prealbumin (g/L)0.11 (0.09, 0.15)0.1 (0.07, 0.12)<0.001*	CRP (mg/L)	95.4 (56.0, 145.8)	124.9 (77.0, 181.1)	0.002*
Albumin/ Globulin1.64 (1.43, 1.96)1.59 (1.36, 1.78)0.162Prealbumin (g/L)0.11 (0.09, 0.15)0.1 (0.07, 0.12)<0.001*	Albumin (g/L)	35.1 (31.8, 37.7)	32.9 (30.8, 35.8)	0.005*
Globulin         Prealbumin (g/L)         0.11 (0.09, 0.15)         0.1 (0.07, 0.12)         <0.001*           INR         1.123 (1.06, 1.21)         1.13 (1.04, 1.23)         0.875           APTT (s)         37.1 (31.2, 43.2)         38.9 (32.5, 43.8)         0.442           PT (s)         14.2 (13.1, 14.9)         14.1 (13.1, 15.2)         0.680           Fibrinogen (mg/dL)         4.5 (3.3, 5.5)         5.1 (3.7, 5.9)         0.024*           TBil (μmol/L)         26.6 (11.7, 63.5)         22.3 (11.9, 42.9)         0.839           ALT (U/L)         31 (20, 47)         30 (17, 48)         0.792           AST (U/L)         23 (16, 33)         23 (16, 30)         0.731           ALP (U/L)         106 (73, 197)         100 (58, 153)         0.110           LDH (U/L)         183 (156, 211)         200 (169, 241)         0.008*	Globulin (g/L)	21.7 (18.7, 24.4)	21.1 (18.6, 23.6)	0.621
(g/L)         INR       1.123 (1.06, 1.21)       1.13 (1.04, 1.23)       0.875         APTT (s)       37.1 (31.2, 43.2)       38.9 (32.5, 43.8)       0.442         PT (s)       14.2 (13.1, 14.9)       14.1 (13.1, 15.2)       0.680         Fibrinogen (mg/dL)       4.5 (3.3, 5.5)       5.1 (3.7, 5.9)       0.024*         TBil (µmol/L)       26.6 (11.7, 63.5)       22.3 (11.9, 42.9)       0.839         ALT (U/L)       31 (20, 47)       30 (17, 48)       0.792         AST (U/L)       23 (16, 33)       23 (16, 30)       0.731         ALP (U/L)       106 (73, 197)       100 (58, 153)       0.110         LDH (U/L)       183 (156, 211)       200 (169, 241)       0.008*		1.64 (1.43, 1.96)	1.59 (1.36, 1.78)	0.162
APTT (s)37.1 (31.2, 43.2)38.9 (32.5, 43.8)0.442PT (s)14.2 (13.1, 14.9)14.1 (13.1, 15.2)0.680Fibrinogen (mg/dL)4.5 (3.3, 5.5)5.1 (3.7, 5.9)0.024*TBil (μmol/L)26.6 (11.7, 63.5)22.3 (11.9, 42.9)0.839ALT (U/L)31 (20, 47)30 (17, 48)0.792AST (U/L)23 (16, 33)23 (16, 30)0.731ALP (U/L)106 (73, 197)100 (58, 153)0.110LDH (U/L)183 (156, 211)200 (169, 241)0.008*		0.11 (0.09, 0.15)	0.1 (0.07, 0.12)	<0.001*
PT (s)14.2 (13.1, 14.9)14.1 (13.1, 15.2)0.680Fibrinogen (mg/dL)4.5 (3.3, 5.5)5.1 (3.7, 5.9)0.024*TBil (μmol/L)26.6 (11.7, 63.5)22.3 (11.9, 42.9)0.839ALT (U/L)31 (20, 47)30 (17, 48)0.792AST (U/L)23 (16, 33)23 (16, 30)0.731ALP (U/L)106 (73, 197)100 (58, 153)0.110LDH (U/L)183 (156, 211)200 (169, 241)0.008*	INR	1.123 (1.06, 1.21)	1.13 (1.04, 1.23)	0.875
Fibrinogen (mg/dL)4.5 (3.3, 5.5)5.1 (3.7, 5.9)0.024*TBil (µmol/L)26.6 (11.7, 63.5)22.3 (11.9, 42.9)0.839ALT (U/L)31 (20, 47)30 (17, 48)0.792AST (U/L)23 (16, 33)23 (16, 30)0.731ALP (U/L)106 (73, 197)100 (58, 153)0.110LDH (U/L)183 (156, 211)200 (169, 241)0.008*	APTT (s)	37.1 (31.2, 43.2)	38.9 (32.5, 43.8)	0.442
(mg/dL)       26.6 (11.7, 63.5)       22.3 (11.9, 42.9)       0.839         ALT (U/L)       31 (20, 47)       30 (17, 48)       0.792         AST (U/L)       23 (16, 33)       23 (16, 30)       0.731         ALP (U/L)       106 (73, 197)       100 (58, 153)       0.110         LDH (U/L)       183 (156, 211)       200 (169, 241)       0.008*	PT (s)	14.2 (13.1, 14.9)	14.1 (13.1, 15.2)	0.680
ALT (U/L)31 (20, 47)30 (17, 48)0.792AST (U/L)23 (16, 33)23 (16, 30)0.731ALP (U/L)106 (73, 197)100 (58, 153)0.110LDH (U/L)183 (156, 211)200 (169, 241)0.008*	U	4.5 (3.3, 5.5)	5.1 (3.7, 5.9)	0.024*
AST (U/L)23 (16, 33)23 (16, 30)0.731ALP (U/L)106 (73, 197)100 (58, 153)0.110LDH (U/L)183 (156, 211)200 (169, 241)0.008*	TBil (µmol/L)	26.6 (11.7, 63.5)	22.3 (11.9, 42.9)	0.839
ALP (U/L)106 (73, 197)100 (58, 153)0.110LDH (U/L)183 (156, 211)200 (169, 241)0.008*	ALT (U/L)	31 (20, 47)	30 (17, 48)	0.792
LDH (U/L) 183 (156, 211) 200 (169, 241) 0.008*	AST (U/L)	23 (16, 33)	23 (16, 30)	0.731
	ALP (U/L)	106 (73, 197)	100 (58, 153)	0.110
GGT (U/L) 104 (39, 194) 67 (31, 172) 0.319	LDH (U/L)	183 (156, 211)	200 (169, 241)	0.008*
	GGT (U/L)	104 (39, 194)	67 (31, 172)	0.319

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; CDC, Clavien–Dindo classification; CRP, C-reactive protein; GGT, gamma glutamyl transferase; Hb, hemoglobin; ICU, intensive care unit; INR, international normalized ratio; LDH, lactate dehydrogenase; MMFR, muscle mass-to-fat ratio; POPF, postoperative pancreatic fistula; PT, prothrombin time; SSI, surgical site infection; TBil, total bilirubin; TNM, tumor-lymph node-metastasis; WBC, white blood cell. \*p < 0.05. KJMS

Variable         OR (95% CI)         p Value         OR (95% CI)         p Value           Sex (frame vs. male)         0.947 (0.333, 1330)         0.967		Univariate analysis		Multivariate analysis	
Age > 65 ys (Yes vs. No)         0.477 (0.365, 1.260)         0.217           BM < 181 kg/m <sup>2</sup> (Yes vs. No)         0.309 (0.067, 1.425)         0.132           VSR < 0.486 (Yes vs. No)         0.272 (0.090, 0.819)         0.021*         0.558 (0.136, 2.287)         0.417           MPD dameter - 3mm (Yes vs. No)         0.700 (4.252, 19-5)         0.001*         10.76 (4.666, 2.4.83)         0.01*           Methods of anastomosis (continuous suture vs. "8-character" suture)         1.307 (0.713, 2.396)         0.386	Variable	OR (95% CI)	p Value	OR (95% CI)	p Value
BMI < 18 kg/m² (Yes vs. No)	Sex (female vs. male)	0.987 (0.533, 1.830)	0.967		
VSR <0.466 (Yes vs. No)	Age > 65 ys (Yes vs. No)	0.677 (0.365, 1.260)	0.217		
MPD diameter <3 mm (Yes vs. No)         9.700 (4.825, 19.50)         0.001         10.76 (4.666, 24.83)         0.001*           Methods of anastomosis (continuous suture vs. "8-character" suture)         1.307 (0.713, 2.396)         0.386	BMI < 18 kg/m <sup>2</sup> (Yes vs. No)	0.309 (0.067, 1.425)	0.132		
Methods of anastomosis (continuous suture vs. "8-character" suture)         1.307 (0.713, 2.396)         0.386           Vascular reconstruction (Yes vs. No)         0.656 (0.067, 6.436)         0.718           Sarcopenia (Yes vs. No)         0.790 (0.433, 1.441)         0.442           MMFR (Low vs. High)         1.709 (0.501, 5.829)         0.302           TNM stage (III vs. HII)         1.709 (0.501, 5.829)         0.553           Preoperative serious underlying disease (Yes vs. No)         2.050 (0.496, 8.480)         0.322           Operation time > 330 min (Yes vs. No)         0.632 (0.312, 0.336)         0.722           Amount of bleeding >300 min (Yes vs. No)         0.632 (0.345, 1.157)         0.137           Pancreatic texture (Soft vs. Hard)         2.570 (1.371, 4.816)         0.003*         1.852 (0.801, 4.280)         0.150           Blood transfusion (Yes vs. No)         0.681 (0.439, 1.649)         0.433	VSR <0.486 (Yes vs. No)	0.272 (0.090, 0.819)	0.021*	0.558 (0.136, 2.287)	0.417
Vascular reconstruction (Yes vs. No)         0.656 (0.067, 6.434)         0.718           Sarcopenia (Yes vs. No)         0.790 (0.433, 1.441)         0.442           MMFK [Low vs. High)         3.039 (1.623, 5.652)         0.011         2.894 (1.214, 6.897)         0.017°           TNM stage (III vs. Hil)         1.709 (0.501, 5.829)         0.392	MPD diameter <3 mm (Yes vs. No)	9.700 (4.825, 19.50)	0.001*	10.76 (4.666, 24.83)	0.001*
Sarcopenia (Yes vs. No)         0.790 (0.433, 1.441)         0.442           MMFR (Low vs. High)         3.039 (1.623, 5.692)         0.001*         2.894 (1.214, 6.899)         0.017*           TNM stage (III vs. I+II)         1.709 (0.501, 5.829)         0.392         IIII (1.1000)         0.012 (1.1000)         IIII (1.1000)         0.012 (1.1000)         IIII (1.1000)         0.012 (1.1000)         IIIII (1.1000)         IIIIII (1.1000)         IIIIII (1.1000)         IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Methods of anastomosis (continuous suture vs. "8-character" suture)	1.307 (0.713, 2.396)	0.386		
MHFR (Low vs. High)         3.039 (1.623, 5.692)         0.01*         2.894 (1.214, 6.899)         0.017*           TNM stage (III vs. I-II)         1.709 (0.501, 5.829)         0.392	Vascular reconstruction (Yes vs. No)	0.656 (0.067, 6.436)	0.718		
TNM stage (III vs. I+II)         1.709 (0.501, 5.829)         0.392           ICU admission status (Yes vs. No)         1.225 (0.627, 2.396)         0.553           Preoperative serious underlying disease (Yes vs. No)         2.050 (0.496, 8.400)         0.322           Operation time > 330 min (Yes vs. No)         1.116 (0.611, 2.036)         0.722           Amount of bleeding > 300 mi. (Yes vs. No)         0.632 (0.345, 1.157)         0.137           Pancreatic texture (Soft vs. Hard)         2.570 (1.371, 4.816)         0.003*         1.852 (0.801, 4.280)         0.150           Blood transfusion (Yes vs. No)         0.851 (0.439, 1.649)         0.633	Sarcopenia (Yes vs. No)	0.790 (0.433, 1.441)	0.442		
ICU admission status (Yes vs. No)         1.225 (0.627, 2.396)         0.553           Preoperative serious underlying disease (Yes vs. No)         2.050 (0.496, 8.480)         0.322           Operation time > 330 min (Yes vs. No)         0.632 (0.345, 1.157)         0.137           Pancreatic texture (Soft vs. Hard)         2.570 (1.371, 4.816)         0.000*         1.852 (0.801, 4.280)         0.150           Blood transfusion (Yes vs. No)         0.631 (0.439, 1.649)         0.633         0.329         1.852 (0.801, 4.280)         0.150           Vascular Invasion (Yes vs. No)         0.667 (0.338, 1.439)         0.329         1.852 (0.801, 4.280)         0.01*           Vascular Invasion (Yes vs. No)         0.667 (0.338, 1.439)         0.329         1.852 (0.801, 4.280)         0.05*           Preoperative laboratory examination         4.624 (1.948, 10.98)         0.00*         4.590 (1.599, 13.17)         0.005*           Preoperative laboratory examination         2.721 (1.064, 6.957)         3.182 (0.827, 12.25)         0.092           Lymphocyte 5.1 x 1.0*0 <sup>7</sup> L (Yes vs. No)         1.321 (0.533, 3.240)         0.543         1.821 (0.827, 12.5)         0.092           Lymphocyte 5.1 x 1.0*0 <sup>7</sup> L (Yes vs. No)         1.321 (0.538, 3.240)         0.643         0.543         0.543           Platelet \$ 1.0 x 1.0*1 (Yes vs. No)         1.321 (0.538, 3.240) <td>MMFR (Low vs. High)</td> <td>3.039 (1.623, 5.692)</td> <td>0.001*</td> <td>2.894 (1.214, 6.899)</td> <td>0.017*</td>	MMFR (Low vs. High)	3.039 (1.623, 5.692)	0.001*	2.894 (1.214, 6.899)	0.017*
Preoperative serious underlying disease (Yes vs. No)         2.050 (0.496, 8.480)         0.322           Operation time > 330 min (Yes vs. No)         1.116 (0.611, 2.036)         0.722           Amount of bleeding > 300 mL (Yes vs. No)         0.632 (0.345, 1.157)         0.137           Pancreatic texture (Soft vs. Hard)         2.570 (1.371, 4.816)         0.003*         1.852 (0.801, 4.280)         0.150           Blood transfusion (Yes vs. No)         0.697 (0.338, 1.439)         0.329	TNM stage (III vs. I-II)	1.709 (0.501, 5.829)	0.392		
Operation time > 330 min (Yes vs. No)         1.114 (0.611, 2.034)         0.722           Amount of bleeding > 300 mL (Yes vs. No)         0.632 (0.345, 1.157)         0.137           Pancreatic texture (Soft vs. Hard)         2.570 (1.371, 4.816)         0.003*         1.852 (0.801, 4.280)         0.150           Blood transfusion (Yes vs. No)         0.697 (0.338, 1.439)         0.627         0.339	ICU admission status (Yes vs. No)	1.225 (0.627, 2.396)	0.553		
Amount of bleeding >300 mL (Yes vs. No)0.632 (0.345, 1.157)0.137Pancreatic texture (Soft vs. Hard)2.570 (1.371, 4.816)0.003*1.852 (0.801, 4.280)0.150Blood transfusion (Yes vs. No)0.851 (0.439, 1.649)0.633	Preoperative serious underlying disease (Yes vs. No)	2.050 (0.496, 8.480)	0.322		
Pancreatic texture (Soft vs. Hard)         2.570 (1.371, 4.816)         0.003*         1.852 (0.801, 4.280)         0.150           Blood transfusion (Yes vs. No)         0.851 (0.439, 1.649)         0.633	Operation time > 330 min (Yes vs. No)	1.116 (0.611, 2.036)	0.722		
Blood transfusion (Yes vs. No)         0.851 (0.439, 1.649)         0.633           Vascular Invasion (Yes vs. No)         0.607 (0.338, 1.439)         0.329           Nerve Invasion (Yes vs. No)         0.600 (0.320, 1.124)         0.111           Lymphatic invasion (Yes vs. No)         4.624 (1.948, 10.98)         0.001*         4.590 (1.599, 13.17)         0.005*           Preoperative laboratory examination            0.037*         3.182 (0.827, 12.25)         0.092           Lymphocyte s 1.1 × 10°/L (Yes vs. No)         1.531 (0.823, 2.846)         0.178             Neutrophil ≥ 6 × 10°/L (Yes vs. No)         1.321 (0.538, 3.240)         0.543             Platelet s 125 × 10°/L (Yes vs. No)         1.495 (0.624, 3.582)         0.367             Globulin < 32 g/L (Yes vs. No)	Amount of bleeding >300 mL (Yes vs. No)	0.632 (0.345, 1.157)	0.137		
Vascular Invasion (Yes vs. No)         0.697 (0.338, 1.439)         0.329           Nerve Invasion (Yes vs. No)         0.600 (0.320, 1.124)         0.111           Lymphatic invasion (Yes vs. No)         4.624 (1.948, 10.98)         0.001*         4.590 (1.599, 13.17)         0.005*           Preoperative laboratory examination	Pancreatic texture (Soft vs. Hard)	2.570 (1.371, 4.816)	0.003*	1.852 (0.801, 4.280)	0.150
Nerve Invasion (Yes vs. No)         0.600 (0.320, 1.124)         0.111           Lymphatic invasion (Yes vs. No)         4.624 (1.948, 10.98)         0.001*         4.590 (1.599, 1.3.17)         0.005*           Preoperative laboratory examination	Blood transfusion (Yes vs. No)	0.851 (0.439, 1.649)	0.633		
Lymphatic invasion (Yes vs. No) $4.624$ (1.948, 10.98) $0.001^*$ $4.590$ (1.599, 13.17) $0.005^*$ Preoperative laboratory examination $VBC \ge 9 \times 10^9/L$ (Yes vs. No) $2.721$ (1.064, 6.957) $0.037^*$ $3.182$ ( $0.827$ , 12.25) $0.092$ Lymphocyte s $1.1 \times 10^9/L$ (Yes vs. No) $1.531$ ( $0.823$ , $2.846$ ) $0.178$ $0.015^*$ Neutrophil $\ge 6 \times 10^9/L$ (Yes vs. No) $1.321$ ( $0.538$ , $3.240$ ) $0.543$ $0.543$ Platelet s $125 \times 10^9/L$ (Yes vs. No) $0.843$ ( $0.211$ , $3.375$ ) $0.809$ $0.02^*$ Hb $\le 100$ g/L (Yes vs. No) $1.495$ ( $0.624$ , $3.582$ ) $0.367$ $0.37^*$ $2.943$ ( $1.061$ , $8.158$ ) $0.038^*$ GRP $\ge 10$ mg/L (Yes vs. No) $1.935$ ( $0.931, 4.023$ ) $0.07^*$ $2.943$ ( $1.061$ , $8.158$ ) $0.038^*$ Albumin $< 32$ g/L (Yes vs. No) $1.143$ ( $0.322, 4.057$ ) $0.836$ $0.066$ Prealbumin $< 0.2$ g/L (Yes vs. No) $1.078$ ( $0.536, 2.167$ ) $0.834$ $0.241$ ( $0.948, 5.300$ ) $0.066$ Prealbumin $< 0.2$ g/L (Yes vs. No) $0.896$ ( $0.491, 1.635$ ) $0.720$ $0.720$ $0.972$ APTT $> 45$ s (Yes vs. No) $0.331$ ( $0.399, 10.37$ ) $0.393$ $0.525$ $0.52$	Vascular Invasion (Yes vs. No)	0.697 (0.338, 1.439)	0.329		
Preoperative laboratory examinationWBC $\geq 9 \times 10^9$ /L (Yes vs. No)2.721 (1.064, 6.957)0.037*3.182 (0.827, 12.25)0.092Lymphocyte $\leq 1.1 \times 10^9$ /L (Yes vs. No)1.531 (0.823, 2.846)0.1781Neutrophil $\geq 6 \times 10^9$ /L (Yes vs. No)1.321 (0.538, 3.240)0.543Platelet $\leq 125 \times 10^9$ /L (Yes vs. No)0.843 (0.211, 3.375)0.809Hb $\leq 100$ g/L (Yes vs. No)1.495 (0.624, 3.582)0.367CRP $\geq 10$ mg/L (Yes vs. No)1.935 (0.931, 4.023)0.077*2.943 (1.061, 8.158)0.038*Albumin < 32 g/L (Yes vs. No)	Nerve Invasion (Yes vs. No)	0.600 (0.320, 1.124)	0.111		
WBC $\geq 9 \times 10^9/L$ (Yes vs. No)2.721 (1.064, 6.957)0.037*3.182 (0.827, 12.25)0.092Lymphocyte $\leq 1.1 \times 10^9/L$ (Yes vs. No)1.531 (0.823, 2.846)0.178Neutrophil $\geq 6 \times 10^9/L$ (Yes vs. No)1.321 (0.538, 3.240)0.543Platelet $\leq 125 \times 10^9/L$ (Yes vs. No)0.843 (0.211, 3.375)0.809Hb $\leq 100 g/L$ (Yes vs. No)1.495 (0.624, 3.582)0.367CRP $\geq 10 mg/L$ (Yes vs. No)1.935 (0.931, 4.023)0.077*2.943 (1.061, 8.158)0.038*Albumin < 32 g/L (Yes vs. No)	Lymphatic invasion (Yes vs. No)	4.624 (1.948, 10.98)	0.001*	4.590 (1.599, 13.17)	0.005*
Lymphocyte $\le 1.1 \times 10^9/L$ (Yes vs. No)1.531 (0.823, 2.846)0.178Neutrophil $\ge 6 \times 10^9/L$ (Yes vs. No)1.321 (0.538, 3.240)0.543Platelet $\le 125 \times 10^9/L$ (Yes vs. No)0.843 (0.211, 3.375)0.809Hb $\le 100$ g/L (Yes vs. No)1.495 (0.624, 3.582)0.367CRP $\ge 10$ mg/L (Yes vs. No)1.935 (0.931, 4.023)0.077*2.943 (1.061, 8.158)0.038*Albumin < 32 g/L (Yes vs. No)	Preoperative laboratory examination				
Neutrophil ≥ 6 × 10 <sup>9</sup> /L (Yes vs. No)1.321 (0.538, 3.240)0.543Platelet ≤ 125 × 10 <sup>9</sup> /L (Yes vs. No)0.843 (0.211, 3.375)0.809Hb ≤ 100 g/L (Yes vs. No)1.495 (0.624, 3.582)0.367CRP ≥ 10 mg/L (Yes vs. No)1.935 (0.931, 4.023)0.077*2.943 (1.061, 8.158)0.038*Albumin < 32 g/L (Yes vs. No)	WBC $\ge 9 \times 10^9$ /L (Yes vs. No)	2.721 (1.064, 6.957)	0.037*	3.182 (0.827, 12.25)	0.092
Platelet $\le 125 \times 10^9/L$ (Yes vs. No)0.843 (0.211, 3.375)0.809Hb $\le 100 g/L$ (Yes vs. No)1.495 (0.624, 3.582)0.367CRP $\ge 10 mg/L$ (Yes vs. No)1.935 (0.931, 4.023)0.077*2.943 (1.061, 8.158)0.038*Albumin < 32 g/L (Yes vs. No)1.143 (0.322, 4.057)0.836Globulin < 25 g/L (Yes vs. No)1.078 (0.536, 2.167)0.834Albumin/Globulin < 1.5 (Yes vs. No)1.874 (1.019, 3.447)0.043*2.241 (0.948, 5.300)0.066Prealbumin < 0.2 g/L (Yes vs. No)0.896 (0.491, 1.635)0.720Prealbumin < 0.2 g/L (Yes vs. No)1.343 (0.588, 3.068)0.484Fibrinogen < 2 mg/dL (Yes vs. No)0.631 (0.301, 1.324)0.223Fibrinogen < 2 mg/dL (Yes vs. No)0.631 (0.301, 1.324)0.273ALT > 60 U/L (Yes vs. No)1.752 (0.923, 3.327)0.087*1.253 (0.458, 3.433)0.602ALT > 100 U/L (Yes vs. No)2.067 (1.111, 3.844)0.022*1.310 (0.475, 3.614)0.602	Lymphocyte $\leq 1.1 \times 10^{9}$ /L (Yes vs. No)	1.531 (0.823, 2.846)	0.178		
Hb ≤ 100 g/L (Yes vs. No)1.495 (0.624, 3.582)0.367CRP ≥ 10 mg/L (Yes vs. No)1.935 (0.931, 4.023)0.077*2.943 (1.061, 8.158)0.038*Albumin < 32 g/L (Yes vs. No)	Neutrophil $\ge 6 \times 10^9$ /L (Yes vs. No)	1.321 (0.538, 3.240)	0.543		
CRP > 10 mg/L (Yes vs. No)1.935 (0.931, 4.023)0.077*2.943 (1.061, 8.158)0.038*Albumin < 32 g/L (Yes vs. No)	Platelet $\leq 125 \times 10^9$ /L (Yes vs. No)	0.843 (0.211, 3.375)	0.809		
Albumin < 32 g/L (Yes vs. No)1.143 (0.322, 4.057)0.836Globulin < 25 g/L (Yes vs. No)	Hb ≤ 100 g/L (Yes vs. No)	1.495 (0.624, 3.582)	0.367		
Globulin < 25 g/L (Yes vs. No)1.078 (0.536, 2.167)0.834Albumin/Globulin < 1.5 (Yes vs. No)	CRP ≥ 10 mg/L (Yes vs. No)	1.935 (0.931, 4.023)	0.077*	2.943 (1.061, 8.158)	0.038*
Albumin/Globulin < 1.5 (Yes vs. No)1.874 (1.019, 3.447)0.043*2.241 (0.948, 5.300)0.066Prealbumin < 0.2 g/L (Yes vs. No)	Albumin < 32 g/L (Yes vs. No)	1.143 (0.322, 4.057)	0.836		
Prealbumin < 0.2 g/L (Yes vs. No)0.896 (0.491, 1.635)0.720APTT > 45 s (Yes vs. No)2.033 (0.399, 10.37)0.393PT > 14 s (Yes vs. No)1.343 (0.588, 3.068)0.484Fibrinogen < 2 mg/dL (Yes vs. No)	Globulin < 25 g/L (Yes vs. No)	1.078 (0.536, 2.167)	0.834		
APTT > 45 s (Yes vs. No)2.033 (0.399, 10.37)0.393PT > 14 s (Yes vs. No)1.343 (0.588, 3.068)0.484Fibrinogen < 2 mg/dL (Yes vs. No)	Albumin/Globulin < 1.5 (Yes vs. No)	1.874 (1.019, 3.447)	0.043*	2.241 (0.948, 5.300)	0.066
PT > 14 s (Yes vs. No)1.343 (0.588, 3.068)0.484Fibrinogen < 2 mg/dL (Yes vs. No)	Prealbumin < 0.2 g/L (Yes vs. No)	0.896 (0.491, 1.635)	0.720		
Fibrinogen < 2 mg/dL (Yes vs. No)	APTT > 45 s (Yes vs. No)	2.033 (0.399, 10.37)	0.393		
TBil > 100 μmol/L (Yes vs. No)       0.631 (0.301, 1.324)       0.223         ALT > 60 U/L (Yes vs. No)       1.752 (0.923, 3.327)       0.087*       1.253 (0.458, 3.433)       0.660         AST > 45 U/L (Yes vs. No)       0.700 (0.370, 1.324)       0.273       0.273         ALP > 100 U/L (Yes vs. No)       2.067 (1.111, 3.844)       0.022*       1.310 (0.475, 3.614)       0.602	PT > 14 s (Yes vs. No)	1.343 (0.588, 3.068)	0.484		
ALT > 60 U/L (Yes vs. No)1.752 (0.923, 3.327)0.087*1.253 (0.458, 3.433)0.660AST > 45 U/L (Yes vs. No)0.700 (0.370, 1.324)0.2730.273ALP > 100 U/L (Yes vs. No)2.067 (1.111, 3.844)0.022*1.310 (0.475, 3.614)0.602	Fibrinogen < 2 mg/dL (Yes vs. No)	0.488 (0.053, 4.459)	0.525		
AST > 45 U/L (Yes vs. No)0.700 (0.370, 1.324)0.273ALP > 100 U/L (Yes vs. No)2.067 (1.111, 3.844)0.022*1.310 (0.475, 3.614)0.602	TBil > 100 μmol/L (Yes vs. No)	0.631 (0.301, 1.324)	0.223		
ALP > 100 U/L (Yes vs. No) 2.067 (1.111, 3.844) 0.022* 1.310 (0.475, 3.614) 0.602	ALT > 60 U/L (Yes vs. No)	1.752 (0.923, 3.327)	0.087*	1.253 (0.458, 3.433)	0.660
	AST > 45 U/L (Yes vs. No)	0.700 (0.370, 1.324)	0.273		
	ALP > 100 U/L (Yes vs. No)	2.067 (1.111, 3.844)	0.022*	1.310 (0.475, 3.614)	0.602
LDIT > 250 0/L (Tes VS. NO) 0.703 (0.215, 2.302) 0.560	LDH > 250 U/L (Yes vs. No)	0.703 (0.215, 2.302)	0.560		
GGT > 60 U/L (Yes vs. No) 0.722 (0.388, 1.344) 0.304	GGT > 60 U/L (Yes vs. No)	0.722 (0.388, 1.344)	0.304		

*Note*: Univariate logistic regression analysis: \*p < 0.1; multivariate logistic regression analysis: \*p < 0.05.

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; GGT, gamma glutamyl transferase; Hb, hemoglobin; ICU, intensive care unit; INR, international normalized ratio; LDH, lactate dehydrogenase; MMFR, muscle mass-to-fat ratio; MPD, main pancreatic duct; POPF, postoperative pancreatic fistula; PT, prothrombin time; TBil, total bilirubin; TNM, tumor-lymph node-metastasis; VSR, visceral-to-subcutaneous adipose tissue area ratio; WBC, white blood cell.

KIMS \_WILEY 9 of 12 Medical Sciences


#### TABLE 5 Univariate and multivariate Cox regression analyses of risk factors for overall survival.


	Univariate analysis		Multivariate analysis	
Variable	HR (95% CI)	p Value	HR (95% CI)	p Value
Sex (female vs. male)	0.983 (0.635, 1.520)	0.938		
Age > 65 (Yes vs. No)	2.027 (1.243, 3.306)	0.005*	1.159 (0.674, 1.993)	0.594
BMI < 18 kg/m <sup>2</sup> (Yes vs. No)	0.774 (0.313, 1.913)	0.579		
VSR <0.486 (Yes vs. No)	0.750 (0.398, 1.415)	0.374		
MPD diameter <3 mm (Yes vs. No)	1.255 (0.803, 1.961)	0.319		
Methods of anastomosis (Continuous suture vs. "8-character" suture)	0.863 (0.562, 1.325)	0.499		
Vascular reconstruction (Yes vs. No)	3.674 (1.140, 11.84)	0.029*	4.120 (1.235, 13.75)	0.021*
Sarcopenia (Yes vs. No)	1.779 (1.144, 2.768)	0.011*	1.778 (1.124, 2.811)	0.014*
MMFR (Low vs. High)	1.705 (1.104, 2.633)	0.016*	1.718 (1.084, 2.723)	0.021*
TNM stage (III vs. I-II)	1.359 (0.626, 2.948)	0.438		
ICU admission status (Yes vs. No)	2.048 (1.187, 3.533)	0.010*	1.907 (1.078, 3.373)	0.026*
Preoperative serious underlying disease (Yes vs. No)	0.565 (0.139, 2.298)	0.425		
Operation time > 330 min (Yes vs. No)	1.177 (0.766, 1.808)	0.456		
Amount of bleeding >300 mL (Yes vs. No)	1.426 (0.915, 2.223)	0.117		
Pancreatic texture (Soft vs. Hard)	1.267 (0.819, 1.960)	0.287		
Blood transfusion (Yes vs. No)	1.579 (1.019, 2.448)	0.041*	1.114 (0.690, 1.799)	0.658
Vascular invasion (Yes vs. No)	1.465 (0.910, 2.357)	0.116		
Nerve invasion (Yes vs. No)	1.879 (1.222, 2.888)	0.004*	1.734 (1.101, 2.730)	0.017*
Lymphatic invasion (Yes vs. No)	1.608 (1.031, 2.508)	0.036*	1.511 (0.952, 2.398)	0.080
Overall complications (Yes vs. No)	1.013 (0.638, 1.610)	0.955		
POPF (Yes vs. No)	0.739 (0.454, 1.202)	0.222		
Bile leakage (Yes vs. No)	1.473 (0.852, 2.546)	0.166		
Chylous fistula (Yes vs. No)	0.599 (0.189 1.897)	0.383		
Gastrointestinalgia (Yes vs. No)	1.390 (0.899, 2.150)	0.139		
Sepsis (Yes vs. No)	1.971 (0.949, 4.092)	0.069*	1.809 (0.822, 3.980)	0.141
Hemorrhage (Yes vs. No)	0.972 (0.486, 1.941)	0.935		
Organ space SSI (Yes vs. No)	1.072 (0.675, 1.702)	0.770		
Incisional SSI (Yes vs. No)	1.349 (0.544, 3.341)	0.518		
Intestinal obstruction (Yes vs. No)	1.248 (0.544, 2.864)	0.601		
Reoperation (Yes vs. No)	1.601 (0.801, 3.200)	0.183		
Thrombotic events (Yes vs. No)	1.657 (0.607, 4.528)	0.325		
Pneumonia (Yes vs. No)	1.219 (0.686, 2.164)	0.500		
Cardiopulmonary events (Yes vs. No)	1.864 (0.933, 3.726)	0.078*	1.791 (0.843, 3.808)	0.130
$CDC \ge III (Yes vs. No)$	1.104 (0.719, 1.696)	0.650		
Postoperative laboratory examination				
WBC $\ge 9 \times 10^{9}$ /L (Yes vs. No)	1.194 (0.728, 1.956)	0.482		
Lymphocyte $\leq 1.1 \times 10^{\circ}/L$ (Yes vs. No)	1.154 (0.638, 2.084)	0.636		
Neutrophil $\geq 6 \times 10^9/L$ (Yes vs. No)	0.749 (0.421, 1.331)	0.325		
Platelet $\leq 125 \times 10^{9}$ /L (Yes vs. No)	1.140 (0.652, 1.994)	0.646		
Hb ≤100 g/L (Yes vs. No)	1.369 (0.880, 2.128)	0.163		
CRP ≥10 mg/L (Yes vs. No)	20.31 (0, 5.8 × 10^6)	0.639		
Albumin <32 g/L (Yes vs. No)	1.092 (0.698, 1.706)	0.701		
Globulin <25 g/L (Yes vs. No)	1.584 (0.839, 2.989)	0.156		
Albumin/Globulin <1.5 (Yes vs. No)	0.773 (0.494, 1.210)	0.260		
Prealbumin <0.2 g/L (Yes vs. No)	0.951 (0.347, 2.602)	0.922		

## TABLE 5 (Continued)

	Univariate analysis	Univariate analysis		Multivariate analysis	
Variable	HR (95% CI)	p Value	HR (95% CI)	p Value	
APTT >45 s (Yes vs. No)	1.375 (0.832, 2.272)	0.214			
PT > 14 s (Yes vs. No)	0.965 (0.629, 1.482)	0.872			
Fibrinogen <2 mg/dL (Yes vs. No)	1.076 (0.340, 3.410)	0.901			
TBil >100 μmol/L (Yes vs. No)	1.418 (0.811, 2.480)	0.220			
ALT >60 U/L (Yes vs. No)	1.024 (0.555, 1.890)	0.939			
AST > 45 U/L (Yes vs. No)	0.642 (0.260, 1.586)	0.337			
ALP > 100 U/L (Yes vs. No)	1.409 (0.915, 2.170)	0.119			
LDH > 250 U/L (Yes vs. No)	0.957 (0.519, 1.763)	0.887			
GGT > 60 U/L (Yes vs. No)	1.465 (0.927, 2.317)	0.102			

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BMI, body mass index; CDC, Clavien–Dindo classification; CRP, C-reactive protein; GGT, gamma glutamyl transferase; Hb, hemoglobin; ICU, intensive care unit; INR, international normalized ratio; LDH, lactate dehydrogenase; MMFR, muscle mass-to-fat ratio; MPD, main pancreatic duct; POPF, postoperative pancreatic fistula; PT, prothrombin time; SSI, surgical site infection; TBil, total bilirubin; TNM, tumor-lymph node-metastasis; VSR, visceralto-subcutaneous adipose tissue area ratio; WBC, white blood cell. \**p* < 0.05.





increasing the risk of POPF. Second, excessive fatty infiltration of the pancreas and soft pancreatic texture lead to pancreatic hypertrophy and a soft pancreatic texture, which results in incomplete anastomosis. Third, excessive abdominal fat and low muscle mass are associated with compromised blood supply to adipose tissues, including the pancreas. Insufficient blood flow to pancreatic tissues can impair wound healing and predispose patients to the development of POPF. Moreover, excessive adipose tissue leads to the production and secretion of adipocytokines such as leptin, tumor necrosis factor- $\alpha$ , interleukin (IL)-1 and IL-6, which can suppress the immune system and delay wound healing, thereby increasing the risk of POPF.<sup>21</sup> In addition, a study indicated that the MPD diameter is smaller in patients with POPF than in patients without POPF.<sup>30</sup> In our study, MPD diameter was an independent predictor of POPF, possibly because a greater MPD diameter facilitates the anastomosis of pancreatojejunostomy, thus reducing the development of POPF. Our study revealed that

postoperative CRP is an independent predictor of POPF. Elevated CRP usually indicates acute inflammation.<sup>31</sup> One study revealed a positive correlation between systemic inflammatory response syndrome and clinically relevant POPF.<sup>32</sup> Thus, CRP may contribute to POPF by activating systemic inflammatory response syndrome.

Our study revealed that the MMFR is an independent predictor of OS in patients after PD and that OS is significantly lower in patients with low MMFR than in those with high MMFR. The high incidence of postoperative complications in patients in the low-MMFR group increased the length of bed rest, abdominal drain placement, and parenteral nutrition, which delays the initiation of postoperative functional exercise and contributes to the poor OS of patients after PD. In addition, our study revealed that postoperative albumin was lower in patients with low MMFRs than in those with high MMFRs, suggesting poorer postoperative nutritional status in the low-MMFR group than in the high-MMFR group. A recent study showed that malnutrition could increase chemotherapeutic toxicity by altering the distribution, metabolism, and clearance of systemic chemotherapeutic agents.<sup>33</sup> Malnutrition can also weaken the immune system, increase susceptibility to infections and delay recovery from chemotherapy-induced side effects, which can result in dose reductions or delays in treatment, thereby compromising its effectiveness.<sup>33</sup> Moreover, malnourished patients have decreased liver function and reduced physical endurance,<sup>34</sup> which increases the difficulty of eliminating chemotherapy drugs and tolerating the side effects of chemotherapy. As a result, these drugs may accumulate at relatively high levels in the body, leading to increased toxicity and a greater risk of side effects. In addition, decreased skeletal muscle mass has been shown to contribute to lower doses of chemotherapy and intolerance of chemotherapy side effects by causing frailty, impairing physical function, reducing quality of life, and increasing toxicity during chemotherapy, ultimately leading to reduced efficacy of the drugs.<sup>35</sup> Excessive visceral fat increases the volume of drug distributed via the accumulation of drugs in fat tissue and alters the pharmacokinetics of chemotherapeutic agents by influencing hepatic and renal drug clearance, both of which result in decreased efficacy and increased toxicity of chemotherapeutic agents.<sup>36</sup> Considering that most patients after PD undergo postoperative adjuvant chemotherapy, which is significantly associated with OS, the mechanisms described above may explain the relationship between low MMFRs and poor OS. One study indicated that sarcopenia is associated with OS but is not associated with postoperative complications,<sup>11</sup> which is compatible with our study. In addition, our study revealed that vascular reconstruction and nerve invasion are independent risk factors for OS. Vascular reconstruction increases the difficulty of the surgical procedure, prolongs the operating time, and increases the risk of intraoperative hemorrhage, which has a negative impact on OS. Furthermore, patients with nerve invasion may be less sensitive to chemotherapy and radiotherapy, and cancer cells invading along nerves may undergo a number of biological changes that make them resistant to conventional chemotherapeutic agents and radiotherapy,<sup>37</sup> both of which might contribute to a short OS.

Our study has several strengths. First, we included only patients with pancreatic cancer who underwent PD, which eliminated the impact of different pathologies and surgical methods on OS. Second, preoperative CT is a routine imaging method for patients with pancreatic cancer, and body composition can be obtained via preoperative CT, which allows patients to avoid additional examinations and costs. This study has several limitations. Because this was a retrospective study involving patients from a single center, there may be selection bias. Therefore, multicenter studies with larger sample sizes are needed to further validate our results.

In conclusion, preoperative muscle mass combined with fat content independently predicted POPF and OS in patients who underwent PD for pancreatic cancer. Patients with a low MMFR had a significantly greater risk of poor prognosis. A low MMFR is often associated with increased inflammation and malnutrition, which suggests that comprehensive anti-inflammatory therapy and nutritional support are warranted for patients with a low MMFR.

# CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

# ORCID

Long-Jie Xu <sup>(b)</sup> https://orcid.org/0000-0002-3609-3654 Sheng-Qiang Zhang <sup>(b)</sup> https://orcid.org/0009-0001-2945-7608 Chun Cao <sup>(b)</sup> https://orcid.org/0000-0002-0443-6069

## REFERENCES

- Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493–502.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
- Okumura S, Kaido T, Hamaguchi Y, Fujimoto Y, Masui T, Mizumoto M, et al. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery. 2015;157:1088–98.
- Wang SY, Hung YL, Hsu CC, Hu CH, Huang RY, Sung CM, et al. Optimal perioperative nutrition therapy for patients undergoing Pancreaticoduodenectomy: a systematic review with a component network meta-analysis. Nutrients. 2021;13:4049.
- Karim SAM, Abdulla KS, Abdulkarim QH, Rahim FH. The outcomes and complications of pancreaticoduodenectomy (Whipple procedure): cross sectional study. Int J Surg. 2018;52:383–7.
- Sandini M, Bernasconi DP, Ippolito D, Nespoli L, Baini M, Barbaro S, et al. Preoperative computed tomography to predict and stratify the risk of severe pancreatic fistula after Pancreatoduodenectomy. Medicine. 2015;94:e1152.
- Khuri S, Mansour S, Obeid A, Azzam A, Borzellino G, Kluger Y. Postpancreatoduodenectomy hemorrhage: association between the causes and the severity of the bleeding. Visc Med. 2021;37: 171–9.
- Detopoulou P, Voulgaridou G, Papadopoulou S. Cancer, phase angle and sarcopenia: the role of diet in connection with lung cancer prognosis. Lung. 2022;200:347–79.
- Ongaro E, Buoro V, Cinausero M, Caccialanza R, Turri A, Fanotto V, et al. Sarcopenia in gastric cancer: when the loss costs too much. Gastric Cancer. 2017;20:563–72.
- Kim YY, Lee J, Jeong WK, Kim ST, Kim JH, Hong JY, et al. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer. 2021;24:457–66.
- Thormann M, Hinnerichs M, Barajas Ordonez F, Saalfeld S, Perrakis A, Croner R, et al. Sarcopenia is an independent prognostic factor in patients with pancreatic cancer – a meta-analysis. Acad Radiol. 2023; 30:1552–61.
- Tsukagoshi M, Araki K, Shirabe K. Pancreatic cancer and sarcopenia: a narrative review of the current status. Int J Clin Oncol. 2024;29: 1055–66.
- Ham S, Choi JH, Shin SG, Lee EJ. High visceral fat-to-muscle ratio is an independent factor that predicts worse overall survival in patients with primary epithelial ovarian, fallopian tube, and peritoneal cancer. J Ovarian Res. 2023;16:19.
- He M, Chen ZF, Zhang L, Gao X, Chong X, Li HS, et al. Associations of subcutaneous fat area and systemic immune-inflammation index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade. J Immunother Cancer. 2023;11: e007054.
- Ashida R, Yamamoto Y, Aramaki T, Sugiura T, Okamura Y, Ito T, et al. Preoperative skeletal muscle fat infiltration is a strong predictor of poorer survival in gallbladder cancer underwent surgery. Clin Nutr ESPEN. 2022;52:60–7.

16. Sakai M, Sohda M, Uchida S, Yamaguchi A, Watanabe T, Saito H, et al. Impact of the ratio of visceral fat area (VFA) to psoas muscle area (PMA) (V/P ratio) on survival for surgically resected esophageal cancer. Ann Surg Oncol. 2022;29:4465-71.

KIMS

- 17. Ronco AL, Boeing H, De Stefani E, Schulz M, Schulze M, Pischon T. A case-control study on fat-to-muscle ratio and risk of breast cancer. Nutr Cancer, 2009:61:466-74.
- 18. Yu PC, Hsu CC, Lee WJ, Liang CK, Chou MY, Lin MH, et al. Muscleto-fat ratio identifies functional impairments and cardiometabolic risk and predicts outcomes: biomarkers of sarcopenic obesity. J Cachexia Sarcopenia Muscle. 2022;13:368-76.
- 19. Tang J, Xu J, Li X, Cao C. Low muscle mass-to-fat ratio is an independent factor that predicts worse overall survival and complications in patients with colon cancer: a retrospective single-center cohort study. Ann Surg Treat Res. 2024;107:68-80.
- 20. Peng YC, Wu CH, Tien YW, Lu TP, Wang YH, Chen BB. Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy. Eur Radiol. 2021; 31:2472-81.
- 21. Jang M, Park HW, Huh J, Lee JH, Jeong YK, Nah YW, et al. Predictive value of sarcopenia and visceral obesity for postoperative pancreatic fistula after pancreaticoduodenectomy analyzed on clinically acquired CT and MRI. Eur Radiol. 2019;29:2417-25.
- 22. Aoki Y, Furukawa K, Suzuki D, Takayashiki T, Kuboki S, Takano S, et al. Influence of sarcopenia as defined by ewgsop2 on complications after pancreaticoduodenectomy and on the prognosis of pancreatic head cancer: a prospective cohort study. Nutrition. 2022;99-100: 111660.
- 23. Nobs SP, Zmora N, Elinav E. Nutrition regulates innate immunity in health and disease. Annu Rev Nutr. 2020;40:189-219.
- 24. Koirala A, Pourafshar N, Daneshmand A, Wilcox CS. Mannemuddhu SS, Arora N. Etiology and Management of Edema: a review. Adv Kidney Dis Health. 2023;30:110-23.
- 25. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011:11:85-97.
- 26. de Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc. 2012;71:332-8.
- 27. Yoo J, Yoon SH, Lee DH, Jang JY. Body composition analysis using convolutional neural network in predicting postoperative pancreatic fistula and survival after pancreatoduodenectomy for pancreatic cancer. Eur J Radiol. 2023;169:111182.
- 28. Cai Z, Yang Y, Fu X, Mao L, Qiu Y. Predictive value of body composition parameters for postoperative complications in patients

who received Pancreaticoduodenectomy. Eur Surg Res. 2023;64: 252 - 60

- 29. Yamane H, Abe T, Amano H, Hanada K, Minami T, Kobayashi T, et al. Visceral adipose tissue and skeletal muscle index distribution predicts severe pancreatic fistula development after Pancreaticoduodenectomy, Anticancer Res. 2018:38:1061-6.
- 30. Akamatsu N, Sugawara Y, Komagome M, Shin N, Cho N, Ishida T, et al. Risk factors for postoperative pancreatic fistula after pancreaticoduodenectomy: the significance of the ratio of the main pancreatic duct to the pancreas body as a predictor of leakage. J Hepatobiliary Pancreat Sci. 2010;17:322-8.
- 31. Sproston NR, Ashworth JJ. Role of c-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:9.
- 32. Ausania F, Gonzalez-Abós C, Martinez-Perez A, Arrocha C, Pineda-Garcés C, Landi F, et al. Postoperative day one systemic inflammatory response syndrome is a powerful early biomarker of clinically relevant pancreatic fistula. HPB. 2023;25:73-80.
- 33. Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition. 2019;67-68:110539.
- 34. Campisano S, La Colla A, Echarte SM, Chisari AN. Interplay between early-life malnutrition, epigenetic modulation of the immune function and liver diseases. Nutr Res Rev. 2019;32:128-45.
- 35. Hilmi M, Jouinot A, Burns R, Pigneur F, Mounier R, Gondin J, et al. Body composition and sarcopenia: the next-generation of personalized oncology and pharmacology? Pharmacol Ther. 2019;196: 135 - 59
- 36. Sheng X, Mittelman SD. The role of adipose tissue and obesity in causing treatment resistance of acute lymphoblastic leukemia. Front Pediatr. 2014;2:53.
- 37. Brunner TB, Seufferlein T. Pancreatic cancer chemoradiotherapy. Best Pract Res Clin Gastroenterol. 2016;30:617-28.

How to cite this article: Xu L-J, Zhang S-Q, Cao C. The impact of the muscle mass-to-fat ratio on the prognosis of patients undergoing pancreaticoduodenectomy for pancreatic cancer. Kaohsiung J Med Sci. 2025;41(2):e12928. https://doi.org/10. 1002/kjm2.12928